Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma

Guardado en:

Detalles Bibliográficos
Autores principales:	Stefan Nierkens, Niels Eijkelkamp, Maaike Nederend, Jeanette Leusen, Mitchell Evers, Marjolein Stip, Kaylee Keller, Hanneke Willemen, Marco Jansen, Chilam Chan, Kevin Budding, Thomas Valerius, Friederike Meyer-Wentrup
Formato:	article
Lenguaje:	EN
Publicado:	BMJ Publishing Group 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/22ca94048a6c4dd2acf901975662eb6e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:22ca94048a6c4dd2acf901975662eb6e
record_format	dspace
spelling	oai:doaj.org-article:22ca94048a6c4dd2acf901975662eb6e2021-12-04T15:00:04ZAnti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma10.1136/jitc-2021-0031632051-1426https://doaj.org/article/22ca94048a6c4dd2acf901975662eb6e2021-10-01T00:00:00Zhttps://jitc.bmj.com/content/9/10/e003163.fullhttps://doaj.org/toc/2051-1426Stefan NierkensNiels EijkelkampMaaike NederendJeanette LeusenMitchell EversMarjolein StipKaylee KellerHanneke WillemenMarco JansenChilam ChanKevin BuddingThomas ValeriusFriederike Meyer-WentrupBMJ Publishing GrouparticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENJournal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Stefan Nierkens Niels Eijkelkamp Maaike Nederend Jeanette Leusen Mitchell Evers Marjolein Stip Kaylee Keller Hanneke Willemen Marco Jansen Chilam Chan Kevin Budding Thomas Valerius Friederike Meyer-Wentrup Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma
format	article
author	Stefan Nierkens Niels Eijkelkamp Maaike Nederend Jeanette Leusen Mitchell Evers Marjolein Stip Kaylee Keller Hanneke Willemen Marco Jansen Chilam Chan Kevin Budding Thomas Valerius Friederike Meyer-Wentrup
author_facet	Stefan Nierkens Niels Eijkelkamp Maaike Nederend Jeanette Leusen Mitchell Evers Marjolein Stip Kaylee Keller Hanneke Willemen Marco Jansen Chilam Chan Kevin Budding Thomas Valerius Friederike Meyer-Wentrup
author_sort	Stefan Nierkens
title	Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma
title_short	Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma
title_full	Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma
title_fullStr	Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma
title_full_unstemmed	Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma
title_sort	anti-gd2 iga kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma
publisher	BMJ Publishing Group
publishDate	2021
url	https://doaj.org/article/22ca94048a6c4dd2acf901975662eb6e
work_keys_str_mv	AT stefannierkens antigd2igakillstumorsbyneutrophilswithoutantibodyassociatedpaininthepreclinicaltreatmentofhighriskneuroblastoma AT nielseijkelkamp antigd2igakillstumorsbyneutrophilswithoutantibodyassociatedpaininthepreclinicaltreatmentofhighriskneuroblastoma AT maaikenederend antigd2igakillstumorsbyneutrophilswithoutantibodyassociatedpaininthepreclinicaltreatmentofhighriskneuroblastoma AT jeanetteleusen antigd2igakillstumorsbyneutrophilswithoutantibodyassociatedpaininthepreclinicaltreatmentofhighriskneuroblastoma AT mitchellevers antigd2igakillstumorsbyneutrophilswithoutantibodyassociatedpaininthepreclinicaltreatmentofhighriskneuroblastoma AT marjoleinstip antigd2igakillstumorsbyneutrophilswithoutantibodyassociatedpaininthepreclinicaltreatmentofhighriskneuroblastoma AT kayleekeller antigd2igakillstumorsbyneutrophilswithoutantibodyassociatedpaininthepreclinicaltreatmentofhighriskneuroblastoma AT hannekewillemen antigd2igakillstumorsbyneutrophilswithoutantibodyassociatedpaininthepreclinicaltreatmentofhighriskneuroblastoma AT marcojansen antigd2igakillstumorsbyneutrophilswithoutantibodyassociatedpaininthepreclinicaltreatmentofhighriskneuroblastoma AT chilamchan antigd2igakillstumorsbyneutrophilswithoutantibodyassociatedpaininthepreclinicaltreatmentofhighriskneuroblastoma AT kevinbudding antigd2igakillstumorsbyneutrophilswithoutantibodyassociatedpaininthepreclinicaltreatmentofhighriskneuroblastoma AT thomasvalerius antigd2igakillstumorsbyneutrophilswithoutantibodyassociatedpaininthepreclinicaltreatmentofhighriskneuroblastoma AT friederikemeyerwentrup antigd2igakillstumorsbyneutrophilswithoutantibodyassociatedpaininthepreclinicaltreatmentofhighriskneuroblastoma
_version_	1718372780449202176

Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma

Ejemplares similares